anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To improve the efficiency of stirring serum so as to attain labor-saving by disposing a container storing serum in a gradient magnetic field of an electromagnet, and applying the electromagnetic force in the counter-gravity direction to serum to generate a convection current in serum, thereby stirring the serum. CONSTITUTION: A container 13 storing serum 23 separated from blood by centrifugation is supported in the internal space of an electromagnet 2. The electromagnet 2 has the central axis in the vertical direction, and generates a stationary gradient magnetic field to apply the electromagnetic force in the counter-gravity direction to the serum 23 in the container 13. In such a condition, the container 13 is vertically reciprocated by a winch 10, taking the center 6 of the electromagnet as a concurrent in the internal space of the electromagnet 2. By this arrangement, the serum 23 in the container 13 is subjected to the application of the electromagnetic force in the counter-gravity direction to generate a convection current. Thus, constant and uniform stirring is performed.
The objective of this study is to determine risk factors that may contribute to exclusion decision from recombinant tissue plasminogen activator (rtPA) in patients with acute ischemic stroke (AIS) with a combined current or history of smoking and obesity. This study was conducted on data from 5469 patients with AIS collected from a regional stroke registry. Risk factors associated with inclusion or exclusion from rtPA were determined using multivariate logistic regression analysis. The adjusted odds ratios and 95% confidence interval for each risk factor were used to predict the increasing odds of an association of a specific risk factor with exclusion from rtPA. In the adjusted analysis, obese patients with AIS with a history of smoking (current and previous) excluded from rtPA were more likely to present with carotid artery stenosis (OR = 0.069, 95% CI 0.011-0.442), diabetes (OR = 0.604, 95% CI 0.366-0.997), higher total cholesterol (OR = 0.975, 95% CI 0.956-0.995), and history of alcohol use (OR = 0.438, 95% CI 0.232-0.828). Higher NIHSS score (OR = 1.051, 95% CI 1.017-1.086), higher triglycerides (OR = 1.004, 95% CI 1.001-1.006), and higher high-density lipoprotein (OR = 1.028, 95% CI 1.000-1.057) were associated with the inclusion for rtPA. Our findings reveal specific risk factors that contribute to the exclusion of patients with AIS with a combined effect of smoking and obesity from rtPA. These findings suggest the need to develop management strategies to improve the use of rtPA for obese patients with AIS with a history of smoking.
Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.
Oxaliplatin Injection is supplied in clear, glass, single-dose vials with gray elastomeric stoppers and aluminum flip-off seals containing 100 mg of oxaliplatin as a clear, colorless, sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.

NDC 0955-1727-20: 100 mg single-dose vial with dark blue flip-off seal individually packaged in a carton.

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze and protect from light (keep in original outer carton). Discard unused portion.

Oxaliplatin is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1The use of gloves is recommended. If a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water.
This was a 3-arm randomized controlled trial, parallel-group study with blind outcomes assessor. Ethical approval was obtained from the Muğla Sıtkı Koçman University Health Sciences Ethics Committee (09.01.2020, decision no: 4). Detailed information about the study was verbally provided to participants, and written informed consent was obtained. The study adhered to the ethical principles of the Helsinki Declaration. The study design adhered to the CONSORT guidelines for rigorous reporting.11 After obtaining consent and confirming the inclusion criteria, a convenience sample of 30 participants was equally and randomly divided into three groups: the CTM group (n=10), CM group (n=10), and control group (n=10). Randomization was carried out by an independent physical therapist, who was not involved in the assessment or treatment of the participants, 1 hour before the baseline measurements. The randomization process involved using opaque and sealed envelopes, each containing a group allocation number generated from a computer-generated random number table. Block randomization was employed to ensure an equal distribution of participants across the groups.

All treatment sessions were administered by the same investigator (C.D) in the study group. The intervention duration was uniform across all groups: 4 consecutive weeks, with 3 sessions per week lasting 15-20 minutes per session. Outcome measurements were taken at the beginning and 4 weeks after the completion of the program. An independent physiotherapist, unaware of the research details and participant groupings, conducted the evaluations.
Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.
COVID-19, which was first identified in 2019 in Wuhan, China, is a respiratory illness caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some patients infected with COVID-19 can remain asymptomatic, most experience a range of symptoms that can be mild to severe. Common symptoms include fever, cough, shortness of breath, fatigue, loss of taste or smell and muscle aches. In severe cases, complications can arise including pneumonia, acute respiratory distress syndrome, organ failure and even death, particularly in older adults or individuals with underlying health conditions. Treatments for COVID-19 include remdesivir, which has been authorised for emergency use in some countries, and dexamethasone, a corticosteroid used to reduce inflammation in severe cases. Biological drugs including monoclonal antibodies, such as casirivimab and imdevimab, have also been authorised for emergency use in certain situations. While these treatments have improved the outcome for many patients, there is still an urgent need for new treatments. Medicinal plants have long served as a valuable source of new drug leads and may serve as a valuable resource in the development of COVID-19 treatments due to their broad-spectrum antiviral activity. To date, various medicinal plant extracts have been studied for their cellular and molecular interactions, with some demonstrating anti-SARS-CoV-2 activity in vitro. This review explores the evaluation and potential therapeutic applications of these plants against SARS-CoV-2. This review summarises the latest evidence on the activity of different plant extracts and their isolated bioactive compounds against SARS-CoV-2, with a focus on the application of plant-derived compounds in animal models and in human studies.
Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
The circadian clock gene system plays a pivotal role in coordinating the daily rhythms of most metabolic processes. It is synchronized with the light-dark cycle and the eating-fasting schedule. Notably, the interaction between meal timing and circadian clock genes (CGs) allows for optimizing metabolic processes at specific times of the day. Breakfast has a powerful resetting effect on the CG network. A misaligned meal pattern, such as skipping breakfast, can lead to a discordance between meal timing and the endogenous CGs, and is associated with obesity and T2D. Conversely, concentrating most calories and carbohydrates (CH) in the early hours of the day upregulates metabolic CG expression, thus promoting improved weight loss and glycemic control. Recently, it was revealed that microorganisms in the gastrointestinal tract, known as the gut microbiome (GM), and its derived metabolites display daily oscillation, and play a critical role in energy and glucose metabolism. The timing of meal intake coordinates the oscillation of GM and GM-derived metabolites, which in turn influences CG expression, playing a crucial role in the metabolic response to food intake. An imbalance in the gut microbiota (dysbiosis) can also reciprocally disrupt CG rhythms. Evidence suggests that misaligned meal timing may cause such disruptions and can lead to obesity and hyperglycemia. This manuscript focuses on the reciprocal interaction between meal timing, GM oscillation, and circadian CG rhythms. It will also review studies demonstrating how aligning meal timing with the circadian clock can reset and synchronize CG rhythms and GM oscillations. This synchronization can facilitate weight loss and improve glycemic control in obesity and those with T2D.
Participant will receive a dose A of GLPG3667 capsules orally once daily (q.d.) for 48 weeks.
The present invention discloses a brain activation substance for preventing and curing encephalopathy and benefiting intelligence. The present invention can be prepared into health care products and medicines used for preventing and curing brain degradation and cerebrovascular diseases, increasing intelligence, and curing nocturia, enuresis, irretention, hypophrenia, senile dementia, parkinsonism dementia and other disease symptoms caused by distempered brain functions or brain functional disorder, can also prevent arthritis, angiosclerosis, blood circulation diseases, rheumatism, Raynaud's syndrome, etc., and has conspicuous curative effect. The present invention is characterized in that the brain activation substance is an extractive of shells (comprising stalks) of shinyleaf yellowhorn wood or branchlet and leaf. The present invention also discloses another brain activation substance for preventing and curing encephalopathy and benefiting intelligence. The second brain activation substance is characterized in that the brain activation substance is a coarse saponin extractive of shells (comprising stalks) of shinyleaf yellowhorn wood or branchlet and leaf. Both brain activation substances can regulate and improve the neural function of the brain. The present invention also discloses the preparation method for both of the two brain activation substances.
Management of plant disease in agro-ecosystems ideally relies on a combination of host genetic resistance, chemical control, and cultural practices. Growers increasingly rely on chemical and genetic options, but their relative benefits in disease control, yield, and economic outcomes are rarely quantified. We explore this relationship for blackleg crown canker disease (caused by Leptosphaeria maculans), a major biotic constraint limiting canola production globally. Data from 20 field trials conducted from 2013 to 2015 in canola-growing regions of Australia were used to assess the effects of host resistance and fungicide treatment on blackleg severity, grain yield, and gross margin. In the absence of fungicide, blackleg disease was 88% lower in the most resistant compared with the most susceptible blackleg resistance category. In the most susceptible resistance category, the most effective fungicide treatment significantly reduced blackleg severity (from 50 to 6%) and increased grain yield (478 kg/ha, 41%) and gross margin (AU$120/ha, 17%). However, the mean benefits of fungicide tended to decrease with increasing levels of genetic resistance, to the point that yield, disease, and gross margin benefits were close to zero in the most resistant cultivars. Overall, these findings suggest that fungicides can reduce blackleg severity, but the benefits of application strongly depend on associated levels of genetic resistance. Canola cultivars with higher genetic resistance reliably reduced blackleg disease and maintained grain yield without the associated cost of fungicide application. The intensification of canola production to meet increasing global demand will require strategies to sustainably manage and protect finite genetic resistance resources to control blackleg disease.
When raising one or two cows on a farm, there were many cases in which the cows defecating white diarrhea caused difficulties. There was a shortage of veterinarians, and a lack of knowledge about how to treat or manage such cases. Although farms having low numbers of cows experience a low number of failed calves, and even though the development of vaccines has enabled the prevention of diarrhea, removing the root cause of diarrhea is preferred over treatment thereof. Although preparing this drug is important, if a cow catches foreign body pneumonia while being fed with the drug, the chances for survival decrease even when the cow is treated. Thus, even when it is a busy season, it is important to feed the drug slowly. Often, those who use the drug for the first time are afraid the dosage is too high. Treating the illnesses of a cow is the responsibility of the farmer, not the veterinarian who occasionally visits for checkups. Being mistaken in thinking that cows should receive a continuous supply of antibiotics, the government relies on the direction of veterinarians to treat cows. However, if all inspection of cows is done by veterinarians, all of the profits will also go to the veterinarians. All farmers must work to discover better treatment methods. Diarrhea is one of the major causes of calf mortality. The present invention provides a composition for treating diarrhea in calves, the composition comprising: 7 g of erberine powder; 7 g of Hilase; 5 g of Sulmet; 7 g of Oxymycin; 10 g of Handong Mi-S; 3.5 g of Ampura-Q; and 10 g of Cow-Lyte. When treating calves having diarrhea with the composition of the present invention, although a single administration of the composition may be effective in some cases, on average, three to four administrations over three days or more were required. The composition of the present invention can be used beneficially to treat diarrhea in calves.
Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
Sacituzumab govitecan (TRODELVY®) is a first-in-class trophoblast cell-surface antigen 2 (Trop-2)-directed antibody and topoisomerase I inhibitor conjugate that is approved globally as monotherapy for the treatment of adults with unresectable locally advanced or metastatic, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-; defined as immunohistochemistry 0, 1+ or 2+ and in situ hybridization-negative) breast cancer who have received endocrine-based therapy and ≥ 2 additional systemic therapies in the advanced setting. In the phase III TROPiCS-02 trial, intravenous sacituzumab govitecan demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine) in adults with metastatic HR+/HER2- breast cancer. Sacituzumab govitecan had a generally manageable tolerability profile in these patients; the most common treatment-related grade ≥ 3 adverse events included neutropenia, diarrhoea, leukopenia, anaemia, fatigue and febrile neutropenia. Sacituzumab govitecan carries regulatory warnings for severe neutropenia and severe diarrhoea. Sacituzumab govitecan demonstrated an overall benefit in terms of health-related quality of life. Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer.
A skin cosmetic comprises a source of oxygen, an excipient and an alkyl phenol, e.g. a tri-alkyl phenol.  Specified sources of oxygen are aqueous hydrogen peroxide, gaseous oxygen incorporated in the excipient by bubbling therethrough.  Specified excipients are polyethylene glycol, which is preferred, and greases and oils. Specified alkyl phenol is 2 : 6-di-tert.-butyl-4-methylphenol. U.S.A. Specification 2,428,745 is referred to.
The present invention discloses an enhancement agent for high intensity focused ultrasound (HIFU) treatment, which is administered to a patient before HIFU treatment and can reduce the level of EEF at the target location to be treated with HIFU. EEF is presented by the expression:  EEF  =   ηPt   / v  (unit: J/mm 3 ), and refers to the HIFU energy needed to effectively treat a tumor per unit volume of the tumor, wherein, η=0.7; P refers to the total acoustic power of HIFU source (unit: W); t refers to the total time of HIFU treatment (unit: s); V refers to the volume of HIFU-induced lesions (unit: mm 3 ). If the amount of EEF at the target location before administration of the enhancement agent is defined as EEF (base)  and the amount of EEF at the target location after administration of the enhancement agent is defined as EEF (measurement) , the ratio between EEF (base)  and EEF (measurement)  is more than 1, preferably more than 2, and more preferably over 4. The use of the enhancement agent for HIFU treatment of the present invention makes it possible to treat deep-seated tumors. In addition, patients with hepatic tumors can be effectively treated without removal of ribs. Accordingly, the present invention discloses methods for increasing acoustic energy deposition at target location during HIFU treatment and screening the enhancement agents for HIFU treatment.
1,235,540. Medicines containing enzymes. ARMOUR PHARMACEUTICAL CO. 2 Dec., 1968, No. 57017/68. Heading A5B. Orally administrable compositions comprise trypsin and/or chymotrypsin in intimate admixture with powdered skim milk, the preparation having a protein content of not more than 1.0 gram per 50,000 AU of enzyme activity. The compositions may contain flavours and may comprise additional medicaments, e.g. penicillin, chloramphenicol tetracycline hydrochloride, sulphisoxazole or sulphaniloamide, which are readily soluble in a pharmaceutically acceptable solvent especially water. The compositions may be dissolved in pharmaceutical liquid carriers for administration, e.g. as a syrup.
AIMS: Familial Hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism that causes an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). Although early diagnosis and treatment of FH can significantly improve the cardiovascular prognosis, this disorder is underdiagnosed and undertreated. For these reasons the Italian Society for the Study of Atherosclerosis (SISA) assembled a Consensus Panel with the task to provide guidelines for FH diagnosis and treatment.
DATA SYNTHESIS: Our guidelines include: i) an overview of the genetic complexity of FH and the role of candidate genes involved in LDL metabolism; ii) the prevalence of FH in the population; iii) the clinical criteria adopted for the diagnosis of FH; iv) the screening for ASCVD and the role of cardiovascular imaging techniques; v) the role of molecular diagnosis in establishing the genetic bases of the disorder; vi) the current therapeutic options in both heterozygous and homozygous FH. Treatment strategies and targets are currently based on low-density lipoprotein cholesterol (LDL-C) levels, as the prognosis of FH largely depends on the magnitude of LDL-C reduction achieved by lipid-lowering therapies. Statins with or without ezetimibe are the mainstay of treatment. Addition of novel medications like PCSK9 inhibitors, ANGPTL3 inhibitors or lomitapide in homozygous FH results in a further reduction of LDL-C levels. LDL apheresis is indicated in FH patients with inadequate response to cholesterol-lowering therapies.
CONCLUSION: FH is a common, treatable genetic disorder and, although our understanding of this disease has improved, many challenges still remain with regard to its identification and management.
BACKGROUND: Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by elevated serum antimitochondrial antibody levels in 90-95 % of cases. However, the exact causal relationship between mitochondrial proteins and PBC remains unclear. This study aims to investigate and clarify this relationship.
METHODS: Genome-wide association data for mitochondrial proteins and PBC were obtained from public databases. The assessment of causal relationships between exposures and outcomes employed the Inverse Variance Weighted (IVW) method, MR Egger regression, and Weighted Median. Sensitivity analyses were systematically carried out to appraise the robustness of the Mendelian Randomization (MR) findings.
RESULTS: The analysis revealed two mitochondrial proteins exhibiting a causal relationship with PBC. Elevated SIRT5 levels demonstrated a positive correlation with an augmented susceptibility to PBC in the IVW approach (odds ratio, OR: 1.2907, 95 % CI: 1.062-1.568, p = 0.0102). Conversely, increased MRPL33 levels were associated with a decreased risk of PBC (OR: 0.8957, 95 % CI: 0.807-0.993, p = 0.0376). Sensitivity analysis corroborated these findings consistently.
CONCLUSION: This investigation advances the notion of a potential causal association between elevated SIRT5 levels and an increased risk of PBC, alongside a decreased risk of PBC linked to elevated MRPL33 levels. The identified mitochondrial proteins may serve as viable biomarkers, offering pertinent insights for the understanding and addressing of PBC.
BACKGROUND Long-term clinical practice has suggested a possible association between ossification of cervical ligament (OCL) and primary osteoporosis (POP). However, there is a lack of relevant research data. This study aimed to clarify the potential relationship between OCL and POP, and propose new strategies for preventing the onset of POP. MATERIAL AND METHODS The study involved 107 patients. The patients' diagnosis included OCL (ossification of the posterior longitudinal ligament, ossification of the ligamentum flavum, and ossification of the nuchal ligament) and POP. Bone mineral density (BMD), types of OCL, types of ossification of posterior longitudinal ligament, age, sex, serum calcium, serum phosphorus, alkaline phosphatase, type I collagen amino-terminal extension peptide, type I collagen degradation products, osteocalcin N-terminal molecular fragments, 25-hydroxyvitamin D, and history of taking steroid drugs were collected. SPSS24.0 and GraphPad Prism 8 were used to obtain the risk factors for POP. RESULTS One-way analysis of variance found that OCL, ossification of posterior longitudinal ligament, alkaline phosphatase, and osteocalcin N-terminal molecular fragments had statistical significance on BMD of the femoral neck (P<0.05). The independent sample t test showed that patient sex had statistical significant effect on BMD (femoral neck) (P=0.036). Incorporating the above factors into multiple linear regression analysis, it was found that OCL, alkaline phosphatase, and osteocalcin N-terminal molecular fragments were risk factors affecting BMD of femoral neck (P<0.05). CONCLUSIONS OCL, osteocalcin N-terminal molecular fragments, and alkaline phosphatase are risk factors for POP.